Data from: First-in-human randomized controlled trial of an oral, replicating Adenovirus 26 vector vaccine for HIV-1

Kathryn E. Stephenson, Michael C. Keefer, Catherine A. Bunce, Doreen Frances, Peter Abbink, Lori F. Maxfield, George H. Neubauer, Joseph Nkolola, Lauren Peter, Christopher Lane, Harriet Park, Carl Verlinde, Angela Lombardo, Christopher Yallop, Menzo Havenga, Patricia Fast, John Treanor & Dan H. Barouch
Background: Live, attenuated viral vectors that express HIV-1 antigens are being investigated as an approach to generating durable immune responses against HIV-1 in humans. We recently developed a replication-competent, highly attenuated Ad26 vector that expresses mosaic HIV-1 Env (rcAd26.MOS1.HIV-Env, “rcAd26”). Here we present the results of a first-in-human, placebo-controlled clinical trial to test the safety, immunogenicity and mucosal shedding of rcAd26 given orally. Methods: Healthy adults were randomly assigned to receive a single oral dose...
1 citation reported since publication in 2018.
285 views reported since publication in 2018.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
65 downloads reported since publication in 2018.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?